A performance evaluation of 90Y dose-calibrator measurements in nuclear pharmacies and clinics in the United States

A blind performance test was conducted to evaluate dose-calibrator measurements at nuclear pharmacies in the United States (US). Two test-sample geometries were chosen to represent those used for measurements of 90Y-ibritumomab tiuxetan (ZEVALIN®). The radioactivity concentration of test-samples was verified by the US National Institute of Standards and Technology. Forty-five results were reported by 10 participants. Eighty percent of reported values were within the US Pharmacopoeia content standard (±10%) for 90Y-ZEVALIN®. All results were within US Nuclear Regulatory Commission conformance limits (±20%) for defining therapeutic misadministrations.